Iodobenzene

Iodobenzene

SCHEMBL4358911

CC(=O)OCC(COC(C)=O)CC(=O)O.CC(=O)OCC(COC(C)=O)CC(=O)O.Ic1ccccc1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
MMP12 P39900 1/20 0.38
DUT P33316 1/20 0.37
KMT2A Q03164 2/20 0.35
PDPK1 O15530 1/20 0.35
FFAR1 O14842 1/20 0.35
CPA1 P15085 2/20 0.34
TSHR P16473 1/20 0.34
GABBR2 O75899 1/20 0.34
GABBR1 Q9UBS5 1/20 0.34
CPB1 P15086 1/20 0.34
CPA3 P15088 1/20 0.34
CPB2 Q96IY4 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
CA2 P00918 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodobenzene SCHEMBL1114451 1.00 ALDH1A1 (0.43) ALDH1A1MMP12DUTKMT2APDPK1
SCHEMBL1114512 0.82 TDP1 (0.42) ALDH1A1
Iodobenzene SCHEMBL4350736 0.76 MAOB (0.43) ALDH1A1
Iodobenzene SCHEMBL27324928 0.75 ALDH1A1 (0.56) ALDH1A1KMT2ATSHRMEN1NPC1
Iodobenzene SCHEMBL4361216 0.75 ALDH1A1 (0.38) ALDH1A1
Iodobenzene SCHEMBL28157391 0.74 ALDH1A1 (0.54) ALDH1A1KMT2ATSHRMEN1NPC1
Iodobenzene SCHEMBL29291766 0.74 MMP12 (0.39) ALDH1A1MMP12KMT2AMEN1CYP3A4
SCHEMBL3503207 0.73 TDP1 (0.38) ALDH1A1CYP3A4
Iodobenzene SCHEMBL29291767 0.73 TDP1 (0.45) ALDH1A1TSHRCYP3A4
Iodobenzene SCHEMBL4348106 0.73 TDP1 (0.45) ALDH1A1MMP12DUTKMT2APDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732029-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-9725402-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-08-08 US disclosed
EP-3067352-A2 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF Cardioxyl Pharmaceuticals Inc. (US) 2016-09-14 EP disclosed
EP-2278975-B1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF CARDIOXYL PHARMACEUTICALS INC (US) 2016-09-07 EP disclosed
US-20160052862-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF CARDIOXYL PHARMACEUTICALS, INC. 2016-02-25 US disclosed
US-20140336137-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF CARDIOXYL PHARMACEUTICALS, INC. 2014-11-13 US disclosed
US-8318705-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2012-11-27 US disclosed
US-20090281062-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF EVOTEC LTD. (GB) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052862-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF NOXO1, TNNI3, HAO2 ALDH1A1 624/4885MMP12 4111/4885DUT 117/4885
US-20140336137-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF NOXO1, TNNI3, HAO2 ALDH1A1 624/4885MMP12 4111/4885DUT 117/4885
US-20090281062-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF NOXO1, TNNI3, HAO2 ALDH1A1 624/4885MMP12 4111/4885DUT 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.